Archives
PTX and LPS Hyperinflammation in Preterm Monocytes
2026-09-17
Schüller and colleagues examined how pentoxifylline modifies LPS-induced activation of monocytes from preterm infants, term infants, and adults in vitro. The study links age-dependent surface-marker changes and cytokine suppression to reduced TLR4 expression, signaling, and phagocytosis, providing a mechanistic framework for interpreting pentoxifylline in neonatal inflammatory research.
XAV-939: Tankyrase Inhibitor for Wnt Research
2026-09-17
XAV-939, also known as NVP-XAV939, is a cell-permeable TNKS1/TNKS2 inhibitor that stabilizes axin and suppresses β-catenin signaling. Its defined activity supports cancer research, fibrotic disease research, osteogenic differentiation studies, and mechanistic Wnt pathway experiments.
Ajugol, Mitophagy, and Chondrocyte Pyroptosis
2026-09-16
The reference study identifies PI3K/AKT/mTOR-dependent suppression of mitophagy as a mechanistic link between mitochondrial dysfunction and chondrocyte pyroptosis in acute gouty arthritis. Its combination of computational prediction, pharmacological pathway tests, cellular assays, and mouse validation provides a framework for evaluating mitochondrial quality control as an anti-inflammatory strategy.
LRPPRC Inhibition and Dasatinib Disrupt OXPHOS
2026-09-16
A 2026 study identifies dasatinib as a synergistic partner for LRPPRC inhibition, showing that the combination blocks OXPHOS through complementary effects on nuclear- and mitochondrial-genome-encoded components. The work provides a mechanistic basis for combination strategies in LRPPRC-high, OXPHOS-dependent tumors while also highlighting the need for validation beyond cell models.
Ruxolitinib (INCB018424) Assay Workflows
2026-09-15
This scenario-driven guide shows how Ruxolitinib (INCB018424), SKU A3012, can improve interpretation of JAK1/2-dependent proliferation, viability, and phospho-signaling assays. It covers assay design, stock preparation, controls, data interpretation, and practical vendor-selection criteria for reproducible myelofibrosis and oncogenic JAK2 research.
Toremifene Citrate for Reliable ER Assays
2026-09-15
A scenario-based guide to using Toremifene Citrate in estrogen receptor, breast cancer, and cell viability studies. It explains how SKU B1513 can support practical assay design through defined receptor activity, DMSO compatibility, concentration guidance, and storage information.
Restoring PTEN with Smarter mRNA Translation
2026-09-14
PTEN mRNA offers a transient, controllable route to interrogate PI3K/Akt biology and therapeutic resistance. This thought-leadership guide connects Cap1 and pseudouridine design with translational experimental strategy, using nanoparticle-mediated PTEN restoration in trastuzumab-resistant breast cancer as a mechanistic anchor.
Lysis Buffer for Rapid Mouse Genotyping
2026-09-14
Build a faster, more consistent mouse genotyping workflow around controlled tissue digestion and DNA release. This guide explains how to use the lysis buffer with proteinase K, improve PCR readiness, and connect reliable genotype assignment with downstream genetic research without overstating what the reagent can prove.
Iptacopan Monotherapy in PNH: Study Findings
2026-09-13
This phase 2 proof-of-concept study evaluated Iptacopan (LNP023), an oral factor B inhibitor, as single-agent therapy in patients with active paroxysmal nocturnal hemoglobinuria. Rapid reductions in hemolysis, improved hemoglobin, and reduced transfusion requirements support proximal alternative-pathway inhibition as a clinically relevant strategy, while the small open-label design limits comparative conclusions.
Tacrine hydrochloride hydrate: assay workflow
2026-09-12
Tacrine hydrochloride hydrate provides a practical benchmark for AChE and BuChE inhibition, while its simple scaffold supports cell-based neuroprotection studies and multi-target drug design. This workflow connects concentration planning, assay controls, translational readouts, and troubleshooting for more reproducible Alzheimer’s disease research.
Entinostat (MS-275) Cancer Research Workflows
2026-09-12
Entinostat (MS-275) enables selective class I HDAC inhibition while helping researchers separate growth arrest from actual cell killing. This workflow-centered guide covers dose-response design, chromatin readouts, retinoblastoma models, and troubleshooting for more interpretable cancer pharmacology data.
LRPPRC Inhibition and Dasatinib Disrupt OXPHOS
2026-09-11
A 2026 study identifies dasatinib as a synergistic partner for LRPPRC inhibition in OXPHOS-dependent cancer models. Its central insight is that the two interventions disrupt complementary OXPHOS gene programs: dasatinib preferentially affects nuclear-encoded genes, whereas LRPPRC inhibition impairs mitochondrial genome-encoded transcripts.
Cy5-UTP for RNA Probe Synthesis and FISH
2026-09-11
Cy5-UTP streamlines fluorescent RNA probe synthesis for FISH, multiplex imaging, and dual-color expression arrays. This practical guide connects labeling chemistry with STAU2 condensate research while emphasizing assay design, optimization, and troubleshooting.
ω-Agatoxin IVA in Epileptogenesis: Study Insights
2026-09-10
This Molecular Neurobiology study shows that selective blockade of P/Q-type Cav2.1 calcium channels with ω-agatoxin IVA suppresses PTZ-associated epileptogenesis in rats while shifting BDNF and cleaved caspase-3 expression toward a pro-survival profile. Its combination of behavioral, freely moving EEG, and regional immunohistochemical analyses provides a useful framework for evaluating Cav2.1 signaling in seizure biology.
DRB: Mechanism, Benchmarks, and RNA Polymerase II
2026-09-10
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) is a CDK-directed transcriptional elongation inhibitor that perturbs RNA polymerase II-dependent RNA synthesis. Its benchmark activities include inhibition of CTD kinases, suppression of hnRNA production in HeLa cells, and inhibition of Tat-enhanced HIV transcription in vitro.
579 records 6/39 page Previous Next First page 上5页 678910 下5页 Last page